Status: Not yet recruiting
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)
The goal of this clinical trial is to determine whether treatment with indapamide can slow the rate of progression in patients with progressive forms of multiple sclerosis (MS). The main question it aims to answer is whether this treatment can reduce the speed at which the walking speed of patients with progressive MS (PMS) worsens. Participants will take an indapamide tablet once daily for 12 months. During this time, among others, their walking speed will be assessed several times.
Participants needed: 75
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Eva M.M. StrijbisUpdated: Aug 14, 2026
Eligibility criteria
Written informed consent obtained [+5]
Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2 [+15]